{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"medRxiv"}],"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T03:30:11Z","timestamp":1792553411675,"version":"4.5.0"},"posted":{"date-parts":[[2023,2,10]]},"group-title":"Epidemiology","reference-count":73,"publisher":"openRxiv","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2023,2,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>As we enter the fourth year of the COVID-19 pandemic, SARS-CoV-2 infections still cause high morbidity and mortality in the United States. During 2020-2022, COVID-19 was one of the leading causes of death in the United States and by far the leading cause among infectious diseases. Vaccination uptake remains low despite this being an effective burden reducing intervention. The development of COVID-19 therapeutics provides hope for mitigating severe clinical outcomes. This modeling study examines combined strategies of vaccination and treatment to reduce the burden of COVID-19 epidemics over the next decade.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We use a validated mathematical model to evaluate the reduction of incident cases, hospitalized cases, and deaths in the United States through 2033 under various levels of vaccination and treatment coverage. We assume that future seasonal transmission patterns for COVID-19 will be similar to those of influenza virus. We account for the waning of infection-induced immunity and vaccine-induced immunity in a future with stable COVID-19 dynamics. Due to uncertainty in the duration of immunity following vaccination or infection, we consider two exponentially-distributed waning rates, with means of 365 days (one year) and 548 days (1.5 years). We also consider treatment failure, including rebound frequency, as a possible treatment outcome.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>As expected, universal vaccination is projected to eliminate transmission and mortality. Under current treatment coverage (13.7%) and vaccination coverage (49%), averages of 89,000 annual deaths (548-day waning) and 120,000 annual deaths (365-day waning) are expected by the end of this decade. Annual mortality in the United States can be reduced below 50,000 per year with &gt;81% annual vaccination coverage, and below 10,000 annual deaths with &gt;84% annual vaccination coverage. Universal treatment reduces hospitalizations by 88% and deaths by 93% under current vaccination coverage. A reduction in vaccination coverage requires a comparatively larger increase in treatment coverage in order for hospitalization and mortality levels to remain unchanged.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Adopting universal vaccination and universal treatment goals in the United States will likely lead to a COVID-19 mortality burden below 50,000 deaths per year, a burden comparable to that of influenza virus.<\/jats:p>\n                <\/jats:sec>","DOI":"10.1101\/2023.02.08.23285658","type":"posted-content","created":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T13:40:25Z","timestamp":1676036425000},"source":"Crossref","is-referenced-by-count":1,"title":["Benefits of near-universal vaccination and treatment access to manage COVID-19 burden in the United States"],"prefix":"10.64898","author":[{"given":"Fuhan","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6789-5900","authenticated-orcid":false,"given":"Thu Nguyen-Anh","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0639-3728","authenticated-orcid":false,"given":"Emily","family":"Howerton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0830-9630","authenticated-orcid":false,"given":"Maciej F","family":"Boni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9988-5712","authenticated-orcid":false,"given":"Joseph L","family":"Servadio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54368","reference":[{"key":"2023021222250697000_2023.02.08.23285658v1.1","unstructured":"CDC. COVID Data Tracker [Internet]. Centers for Disease Control and Prevention. 2020 [cited 2023 Jan 23]. Available from: https:\/\/covid.cdc.gov\/covid-data-tracker"},{"key":"2023021222250697000_2023.02.08.23285658v1.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)02346-1"},{"key":"2023021222250697000_2023.02.08.23285658v1.3","first-page":"32","article-title":"Identifying age-and sex-specific COVID-19 mortality trends over time in six countries","volume":"128","year":"2022","journal-title":"Int J Infect Dis"},{"key":"2023021222250697000_2023.02.08.23285658v1.4","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwt235"},{"key":"2023021222250697000_2023.02.08.23285658v1.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2021.11.009"},{"key":"2023021222250697000_2023.02.08.23285658v1.6","doi-asserted-by":"crossref","unstructured":"Lopez Bernal J , Andrews N , Gower C , Robertson C , Stowe J , Tessier E , et al. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. BMJ. 2021 May 13;373:1088.","DOI":"10.1136\/bmj.n1088"},{"key":"2023021222250697000_2023.02.08.23285658v1.7","doi-asserted-by":"crossref","first-page":"110894","DOI":"10.1016\/j.jtbi.2021.110894","article-title":"Network models to evaluate vaccine strategies towards herd immunity in COVID-19","volume":"531","year":"2021","journal-title":"J Theor Biol"},{"issue":"1","key":"2023021222250697000_2023.02.08.23285658v1.8","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1186\/s12874-021-01458-9","article-title":"Impact of vaccine prioritization strategies on mitigating COVID-19: an agent-based simulation study using an urban region in the United States","volume":"21","year":"2021","journal-title":"BMC Med Res Methodol"},{"key":"2023021222250697000_2023.02.08.23285658v1.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2020.12.075"},{"issue":"19","key":"2023021222250697000_2023.02.08.23285658v1.10","doi-asserted-by":"crossref","first-page":"719","DOI":"10.15585\/mmwr.mm7019e3","article-title":"Modeling of Future COVID-19 Cases, Hospitalizations, and Deaths, by Vaccination Rates and Nonpharmaceutical Intervention Scenarios - United States, April-September 2021","volume":"70","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2023021222250697000_2023.02.08.23285658v1.11","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2118542"},{"issue":"48","key":"2023021222250697000_2023.02.08.23285658v1.12","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.15585\/mmwr.mm7148e2","article-title":"Paxlovid Associated with Decreased Hospitalization Rate Among Adults with COVID-19 - United States, April-September 2022","volume":"71","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2023021222250697000_2023.02.08.23285658v1.13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2116846"},{"key":"2023021222250697000_2023.02.08.23285658v1.14","doi-asserted-by":"crossref","unstructured":"Dougan M , Azizad M , Chen P , Feldman B , Frieman M , Igbinadolor A , et al. Bebtelovimab, alone or together with bamlanivimab and etesevimab, as a broadly neutralizing monoclonal antibody treatment for mild to moderate, ambulatory COVID-19 [Internet]. medRxiv; 2022 [cited 2023 Feb 8]. p. 2022.03.10.22272100. Available from: https:\/\/www.medrxiv.org\/content\/10.1101\/2022.03.10.22272100v1","DOI":"10.1101\/2022.03.10.22272100"},{"key":"2023021222250697000_2023.02.08.23285658v1.15","doi-asserted-by":"crossref","unstructured":"Ison MG , Hayden FG . Antiviral Agents Against Respiratory Viruses. Infectious Diseases. 2017;1318\u20131326.e2.","DOI":"10.1016\/B978-0-7020-6285-8.00154-4"},{"issue":"4","key":"2023021222250697000_2023.02.08.23285658v1.16","first-page":"eabf9868","article-title":"SARS-CoV-2 epidemic after social and economic reopening in three U.S","volume":"8","year":"2022","journal-title":"states reveals shifts in age structure and clinical characteristics. Science Advances"},{"issue":"5","key":"2023021222250697000_2023.02.08.23285658v1.17","doi-asserted-by":"crossref","first-page":"e2214171","DOI":"10.1001\/jamanetworkopen.2022.14171","article-title":"SARS-CoV-2 Attack Rate and Population Immunity in Southern New England, March 2020 to May 2021","volume":"5","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2023021222250697000_2023.02.08.23285658v1.18","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-021-02038-w"},{"key":"2023021222250697000_2023.02.08.23285658v1.19","unstructured":"Rhode Island COVID-19 Data FAQ [Internet]. [cited 2023 Feb 7]. Available from: https:\/\/ridoh-covid-19-data-faq-rihealth-rihealth.hub.arcgis.com\/"},{"key":"2023021222250697000_2023.02.08.23285658v1.20","unstructured":"COVID-19 Reported Patient Impact and Hospital Capacity by State Timeseries | HealthData.gov [Internet]. [cited 2023 Feb 7]. Available from: https:\/\/healthdata.gov\/Hospital\/COVID-19-Reported-Patient-Impact-and-Hospital-Capa\/g62h-syeh"},{"key":"2023021222250697000_2023.02.08.23285658v1.21","unstructured":"COVID-19 Vaccinations in the United States,Jurisdiction | Data | Centers for Disease Control and Prevention [Internet]. [cited 2023 Feb 7]. Available from: https:\/\/data.cdc.gov\/Vaccinations\/COVID-19-Vaccinations-in-the-United-States-Jurisdi\/unsk-b7fc"},{"key":"2023021222250697000_2023.02.08.23285658v1.22","unstructured":"Influenza Vaccination Coverage for All Ages (6+ Months) | Data | Centers for Disease Control and Prevention [Internet]. [cited 2023 Feb 7]. Available from: https:\/\/data.cdc.gov\/Flu-Vaccinations\/Influenza-Vaccination-Coverage-for-All-Ages-6-Mont\/vh55-3he6"},{"key":"2023021222250697000_2023.02.08.23285658v1.23","unstructured":"COVID-19 Therapeutics Thresholds, Orders, and Replenishment by Jurisdiction | HHS\/ASPR [Internet]. [cited 2023 Feb 7]. Available from: https:\/\/aspr.hhs.gov:443\/COVID-19\/Therapeutics\/Orders\/Pages\/default.aspx"},{"key":"2023021222250697000_2023.02.08.23285658v1.24","doi-asserted-by":"crossref","unstructured":"Boucau J , Uddin R , Marino C , Regan J , Flynn JP , Choudhary MC , et al. Characterization of virologic rebound following nirmatrelvir-ritonavir treatment for COVID-19. Clin Infect Dis. 2022 Jun 1;ciac512.","DOI":"10.1101\/2022.05.24.22275326"},{"issue":"11","key":"2023021222250697000_2023.02.08.23285658v1.25","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMc2206449","article-title":"Rebound of SARS-CoV-2 Infection after Nirmatrelvir-Ritonavir Treatment","volume":"387","year":"2022","journal-title":"N Engl J Med"},{"issue":"4","key":"2023021222250697000_2023.02.08.23285658v1.26","first-page":"436","article-title":"COVID-19 \u201cRebound\u201d associated with nirmatrelvir\/ritonavir pre-hospital therapy","volume":"85","year":"2022","journal-title":"Journal of Infection"},{"key":"2023021222250697000_2023.02.08.23285658v1.27","doi-asserted-by":"crossref","unstructured":"Ranganath N , O\u2019Horo JC , Challener DW , Tulledge-Scheitel SM , Pike ML , O\u2019Brien M , et al. Rebound Phenomenon After Nirmatrelvir\/Ritonavir Treatment of Coronavirus Disease 2019 (COVID-19) in High-Risk Persons. Clinical Infectious Diseases. 2022 Jun 14;ciac481.","DOI":"10.1093\/cid\/ciac481"},{"issue":"5","key":"2023021222250697000_2023.02.08.23285658v1.28","doi-asserted-by":"crossref","first-page":"e134","DOI":"10.1016\/j.jinf.2022.08.012","article-title":"Rapid COVID-19 rebound in a severe COVID-19 patient during 20-day course of Paxlovid","volume":"85","year":"2022","journal-title":"Journal of Infection"},{"key":"2023021222250697000_2023.02.08.23285658v1.29","doi-asserted-by":"crossref","unstructured":"Wang L , Berger NA , Davis PB , Kaelber DC , Volkow ND , Xu R. COVID-19 rebound after Paxlovid and Molnupiravir during January-June 2022 [Internet]. Infectious Diseases (except HIV\/AIDS); 2022 Jun [cited 2023 Jan 3]. Available from: http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2022.06.21.22276724","DOI":"10.1101\/2022.06.21.22276724"},{"key":"2023021222250697000_2023.02.08.23285658v1.30","doi-asserted-by":"crossref","unstructured":"Li H , Gao M , You H , Zhang P , Pan Y , Li N , et al. Association of Nirmatrelvir\/Ritonavir Treatment on Upper Respiratory Severe Acute Respiratory Syndrome Coronavirus 2 Reverse Transcription-Polymerase Chain Reaction (SARS-Cov-2 RT-PCR) Negative Conversion Rates Among High-Risk Patients With Coronavirus Disease 2019 (COVID-19). Clinical Infectious Diseases. 2022 Jul 23;ciac600.","DOI":"10.1093\/cid\/ciac600"},{"key":"2023021222250697000_2023.02.08.23285658v1.31","unstructured":"Pfizer. Pfizer\u2019s Novel COVID-19 Oral Antiviral Treatment Candidate Reduced Risk of Hospitalization or Death by 89% in Interim Analysis of Phase 2\/3 EPIC-HR Study. Nota de prensa. 2021;"},{"key":"2023021222250697000_2023.02.08.23285658v1.32","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2119451"},{"key":"2023021222250697000_2023.02.08.23285658v1.33","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-072141"},{"key":"2023021222250697000_2023.02.08.23285658v1.34","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-3946736(21)02183-8"},{"issue":"8","key":"2023021222250697000_2023.02.08.23285658v1.35","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1093\/infdis\/jiab295","article-title":"Naturally Acquired SARS-CoV-2 Immunity Persists for Up to 11 Months Following Infection","volume":"224","year":"2021","journal-title":"The Journal of Infectious Diseases"},{"key":"2023021222250697000_2023.02.08.23285658v1.36","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-022-07418-y"},{"key":"2023021222250697000_2023.02.08.23285658v1.37","doi-asserted-by":"crossref","unstructured":"Bobrovitz N , Ware H , Ma X , Li Z , Hosseini R , Cao C , et al. Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regression. Lancet Infect Dis. 2023 Jan 18;S1473-3099(22)00801-5.","DOI":"10.1016\/S1473-3099(22)00801-5"},{"key":"2023021222250697000_2023.02.08.23285658v1.38","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00575-4"},{"issue":"6","key":"2023021222250697000_2023.02.08.23285658v1.39","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S1473-3099(22)00143-8","article-title":"Risk of SARS-CoV-2 reinfection and COVID-19 hospitalisation in individuals with natural and hybrid immunity: a retrospective, total population cohort study in Sweden","volume":"22","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"2023021222250697000_2023.02.08.23285658v1.40","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m1923"},{"issue":"8","key":"2023021222250697000_2023.02.08.23285658v1.41","doi-asserted-by":"crossref","first-page":"e2228008","DOI":"10.1001\/jamanetworkopen.2022.28008","article-title":"Incubation Period of COVID-19 Caused by Unique SARS-CoV-2 Strains: A Systematic Review and Meta-analysis","volume":"5","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"3","key":"2023021222250697000_2023.02.08.23285658v1.42","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1056\/NEJMc2202092","article-title":"Duration of Shedding of Culturable Virus in SARS-CoV-2 Omicron (BA.1) Infection","volume":"387","year":"2022","journal-title":"N Engl J Med"},{"key":"2023021222250697000_2023.02.08.23285658v1.43","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01887-z"},{"key":"2023021222250697000_2023.02.08.23285658v1.44","unstructured":"COVID-19 Nursing Home Data - Centers for Medicare & Medicaid Services Data [Internet]. [cited 2023 Jan 8]. Available from: https:\/\/data.cms.gov\/covid-19\/covid-19-nursing-home-data"},{"key":"2023021222250697000_2023.02.08.23285658v1.45","doi-asserted-by":"crossref","unstructured":"Nyberg T , Ferguson NM , Nash SG , Webster HH , Flaxman S , Andrews N , et al. Comparative Analysis of the Risks of Hospitalisation and Death Associated with SARS-CoV-2 Omicron (B.1.1.529) and Delta (B.1.617.2) Variants in England. SSRN Journal [Internet]. 2022 [cited 2023 Jan 3]; Available from: https:\/\/www.ssrn.com\/abstract=4025932","DOI":"10.2139\/ssrn.4025932"},{"key":"2023021222250697000_2023.02.08.23285658v1.46","doi-asserted-by":"crossref","unstructured":"Servadio JL , Thai PQ , Choisy M , Boni MF . Repeatability and timing of tropical influenza epidemics [Internet]. medRxiv; 2022 [cited 2023 Jan 24]. p. 2022.11.04.22281944. Available from: https:\/\/www.medrxiv.org\/content\/10.1101\/2022.11.04.22281944v1","DOI":"10.1101\/2022.11.04.22281944"},{"key":"2023021222250697000_2023.02.08.23285658v1.47","unstructured":"CDC. Burden of Influenza [Internet]. Centers for Disease Control and Prevention. 2022 [cited 2023 Jan 10]. Available from: https:\/\/www.cdc.gov\/flu\/about\/burden\/index.html"},{"key":"2023021222250697000_2023.02.08.23285658v1.48","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2108891"},{"key":"2023021222250697000_2023.02.08.23285658v1.49","doi-asserted-by":"crossref","unstructured":"Wang L , Volkow ND , Davis PB , Berger NA , Kaelber DC , Xu R. COVID-19 rebound after Paxlovid treatment during Omicron BA.5 vs BA.2.12.1 subvariant predominance period [Internet]. Infectious Diseases (except HIV\/AIDS); 2022 Aug [cited 2023 Jan 3]. Available from: http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2022.08.04.22278450","DOI":"10.1101\/2022.08.04.22278450"},{"issue":"6","key":"2023021222250697000_2023.02.08.23285658v1.50","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1056\/NEJMoa2116044","article-title":"Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients","volume":"386","year":"2022","journal-title":"N Engl J Med"},{"key":"2023021222250697000_2023.02.08.23285658v1.51","doi-asserted-by":"publisher","DOI":"10.1126\/science.abe6959"},{"key":"2023021222250697000_2023.02.08.23285658v1.52","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abf1374"},{"key":"2023021222250697000_2023.02.08.23285658v1.53","doi-asserted-by":"crossref","first-page":"100389","DOI":"10.1016\/j.lanwpc.2022.100389","article-title":"The allocation of COVID-19 vaccines and antivirals against emerging SARS-CoV-2 variants of concern in East Asia and Pacific region: A modelling study","volume":"21","year":"2022","journal-title":"The Lancet Regional Health - Western Pacific"},{"key":"2023021222250697000_2023.02.08.23285658v1.54","doi-asserted-by":"crossref","first-page":"106822","DOI":"10.1016\/j.cct.2022.106822","article-title":"The comparative effectiveness of COVID-19 monoclonal antibodies: A learning health system randomized clinical trial","volume":"119","year":"2022","journal-title":"Contemp Clin Trials"},{"issue":"10339","key":"2023021222250697000_2023.02.08.23285658v1.55","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1016\/S0140-6736(22)00519-0","article-title":"Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses","volume":"399","author":"WHO Solidarity Trial Consortium","year":"2022","journal-title":"Lancet"},{"key":"2023021222250697000_2023.02.08.23285658v1.56","unstructured":"Matrajt L , Brown ER , Cohen MS , Dimitrov D , Janes H. Could widespread use of antiviral treatment curb the COVID-19 pandemic? A modeling study."},{"key":"2023021222250697000_2023.02.08.23285658v1.57","unstructured":"Respiratory Syncytial Virus (RSV) | NIH: National Institute of Allergy and Infectious Diseases [Internet]. [cited 2023 Jan 23]. Available from: https:\/\/www.niaid.nih.gov\/diseases-conditions\/respiratory-syncytial-virus-rsv"},{"key":"2023021222250697000_2023.02.08.23285658v1.58","unstructured":"Underlying Cause of Death, 1999-2020 Request [Internet]. [cited 2023 Jan 23]. Available from: https:\/\/wonder.cdc.gov\/ucd-icd10.html"},{"issue":"3","key":"2023021222250697000_2023.02.08.23285658v1.59","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/s41562-021-01056-1","article-title":"Measuring the impact of COVID-19 vaccine misinformation on vaccination intent in the UK and USA","volume":"5","year":"2021","journal-title":"Nat Hum Behav"},{"issue":"5","key":"2023021222250697000_2023.02.08.23285658v1.60","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/j.vaccine.2022.12.059","article-title":"A systematic review of communication interventions for countering vaccine misinformation","volume":"41","year":"2023","journal-title":"Vaccine"},{"key":"2023021222250697000_2023.02.08.23285658v1.61","doi-asserted-by":"crossref","first-page":"698111","DOI":"10.3389\/fpubh.2021.698111","article-title":"Predictors of COVID-19 Vaccine Acceptance, Intention, and Hesitancy: A Scoping Review","volume":"9","year":"2021","journal-title":"Front Public Health"},{"key":"2023021222250697000_2023.02.08.23285658v1.62","doi-asserted-by":"publisher","DOI":"10.1007\/s00285-002-0186-2"},{"key":"2023021222250697000_2023.02.08.23285658v1.63","doi-asserted-by":"publisher","DOI":"10.1007\/s11538-010-9623-3"},{"key":"2023021222250697000_2023.02.08.23285658v1.64","doi-asserted-by":"publisher","DOI":"10.1001\/archpedi.157.4.381"},{"issue":"1","key":"2023021222250697000_2023.02.08.23285658v1.65","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s12916-020-01872-8","article-title":"The impact of non-pharmaceutical interventions on SARS-CoV-2 transmission across 130 countries and territories","volume":"19","author":"CMMID COVID-19 Working Group","year":"2021","journal-title":"BMC Med"},{"key":"2023021222250697000_2023.02.08.23285658v1.66","doi-asserted-by":"crossref","unstructured":"Boehmer TK. Racial and Ethnic Disparities in Outpatient Treatment of COVID-19 - United States, January-July 2022. MMWR Morb Mortal Wkly Rep [Internet]. 2022 [cited 2023 Jan 24];71. Available from: https:\/\/www.cdc.gov\/mmwr\/volumes\/71\/wr\/mm7143a2.htm","DOI":"10.15585\/mmwr.mm7143a2"},{"issue":"1","key":"2023021222250697000_2023.02.08.23285658v1.67","doi-asserted-by":"crossref","first-page":"e529","DOI":"10.1093\/cid\/ciab1039","article-title":"Fair Allocation of Scarce Therapies for Coronavirus Disease 2019 (COVID-19)","volume":"75","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2023021222250697000_2023.02.08.23285658v1.68","unstructured":"Archive: COVID-19 Vaccination and Case Trends by Age Group, United States | Data | Centers for Disease Control and Prevention [Internet]. [cited 2023 Feb 5]. Available from: https:\/\/data.cdc.gov\/Vaccinations\/Archive-COVID-19-Vaccination-and-Case-Trends-by-Ag\/gxj9-t96f"},{"issue":"12","key":"2023021222250697000_2023.02.08.23285658v1.69","doi-asserted-by":"crossref","first-page":"e2245086","DOI":"10.1001\/jamanetworkopen.2022.45086","article-title":"Incidence of Viral Rebound After Treatment With Nirmatrelvir-Ritonavir and Molnupiravir","volume":"5","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2023021222250697000_2023.02.08.23285658v1.70","doi-asserted-by":"crossref","unstructured":"Deo R , Choudhary MC , Moser C , Ritz J , Daar ES , Wohl DA , et al. Viral and Symptom Rebound in Untreated COVID-19 Infection. medRxiv. 2022 Aug 2;2022.08.01.22278278.","DOI":"10.1101\/2022.08.01.22278278"},{"key":"2023021222250697000_2023.02.08.23285658v1.71","doi-asserted-by":"crossref","unstructured":"Soares H , Baniecki M , Cardin RD , Leister-Tebbe H , Zhu Y , Guan S , et al. Viral Load Rebound in Placebo and Nirmatrelvir-Ritonavir Treated COVID-19 Patients is not Associated with Recurrence of Severe Disease or Mutations [Internet]. 2022 [cited 2023 Feb 8]. Available from: https:\/\/www.researchsquare.com","DOI":"10.21203\/rs.3.rs-1720472\/v2"},{"key":"2023021222250697000_2023.02.08.23285658v1.72","doi-asserted-by":"crossref","unstructured":"Jochmans D , Liu C , Donckers K , Stoycheva A , Boland S , Stevens SK , et al. The substitutions L50F, E166A and L167F in SARS-CoV-2 3CLpro are selected by a protease inhibitor in vitro and confer resistance to nirmatrelvir [Internet]. bioRxiv; 2022 [cited 2023 Jan 12]. p. 2022.06.07.495116. Available from: https:\/\/www.biorxiv.org\/content\/10.1101\/2022.06.07.495116v2","DOI":"10.1101\/2022.06.07.495116"},{"issue":"51","key":"2023021222250697000_2023.02.08.23285658v1.73","doi-asserted-by":"crossref","first-page":"eadd7197","DOI":"10.1126\/sciadv.add7197","article-title":"Nirmatrelvir-resistant SARS-CoV-2 variants with high fitness in an infectious cell culture system","volume":"8","year":"2022","journal-title":"Science Advances"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2023.02.08.23285658","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T19:26:45Z","timestamp":1768505205000},"score":1,"resource":{"primary":{"URL":"http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2023.02.08.23285658"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,10]]},"references-count":73,"URL":"https:\/\/doi.org\/10.1101\/2023.02.08.23285658","relation":{"is-preprint-of":[{"id-type":"doi","id":"10.1186\/s12916-023-03025-z","asserted-by":"subject"}]},"subject":[],"published":{"date-parts":[[2023,2,10]]},"subtype":"preprint"}}